Barbara Duncan
Chairman at FUSN PHAR
Net worth: 376 412 $ as of 2024-03-30
Profile
Barbara Gayle Duncan is currently serving as Chairman at Fusion Pharmaceuticals, Inc., Independent Director at Halozyme Therapeutics, Inc., Independent Director at Atea Pharmaceuticals, Inc., Independent Director at Ovid Therapeutics, Inc., Director at Halozyme, Inc., and Non-Executive Director at Versanis Bio, Inc. She has previously served as Independent Director at Immunomedics, Inc., Chief Executive & Financial Officer, Director at DOV Pharmaceutical, Inc., Director at Edgemont Pharmaceuticals LLC, Director-Corporate Finance at SBC Warburg Dillon Read Corporate Finance AG, Director at Innoviva, Inc., Independent Director at Aevi Genomic Medicine, Inc., Non-Executive Director at Adaptimmune Ltd., Independent Director at Jounce Therapeutics, Inc., Independent Director at ObsEva SA, Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc., and Principal at PepsiCo, Inc. She has also served as Vice President-Corporate Finance Division at Lehman Brothers, Inc. and Principal at Deloitte & Touche LLP.
Ms. Duncan holds an undergraduate degree from Louisiana State University and an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-05-04 | 9,253 ( 0.01% ) | 376 412 $ | 2024-03-30 | |
2023-04-02 | 0 ( -.--% ) | - $ | 2024-03-30 | |
OVID THERAPEUTICS INC.
-.--% | 2024-02-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
2023-06-15 | 0 ( -.--% ) | - $ | 2024-03-30 | |
2023-06-13 | 0 ( -.--% ) | - $ | 2024-03-30 |
Barbara Duncan active positions
Companies | Position | Start |
---|---|---|
OVID THERAPEUTICS INC. | Director/Board Member | 2017-06-13 |
FUSN PHAR | Chairman | 2020-11-01 |
ATEA PHARMACEUTICALS, INC. | Director/Board Member | 2020-09-30 |
HALOZYME THERAPEUTICS, INC. | Director/Board Member | 2023-02-02 |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Director/Board Member | 2022-07-19 |
Halozyme, Inc.
Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a private company based in San Diego, CA. | Director/Board Member | 2023-01-31 |
Former positions of Barbara Duncan
Companies | Position | End |
---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Director/Board Member | 2023-05-31 |
JOUNCE THERAPEUTICS, INC. | Director/Board Member | 2023-05-02 |
OBSEVA SA | Director/Board Member | 2021-05-27 |
░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Barbara Duncan
Louisiana State University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 9 |
---|---|
PEPSICO, INC. | Consumer Non-Durables |
HALOZYME THERAPEUTICS, INC. | Health Technology |
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
ATEA PHARMACEUTICALS, INC. | Health Technology |
OVID THERAPEUTICS INC. | Health Technology |
INNOVIVA, INC. | Health Technology |
OBSEVA SA | Health Technology |
FUSN PHAR | Health Technology |
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Private companies | 11 |
---|---|
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
Edgemont Pharmaceuticals LLC
Edgemont Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
SBC Warburg Dillon Read Corporate Finance AG | Finance |
Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
Halozyme, Inc.
Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a private company based in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Barbara Duncan